- Home
- ACM vs ITCI Comparison
ACM vs ITCI Comparison
Compare ACM & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACM
- ITCI
- Stock Information
- Founded
- ACM 1980
- ITCI 2002
- Country
- ACM United States
- ITCI United States
- Employees
- ACM N/A
- ITCI N/A
- Industry
- ACM Military/Government/Technical
- ITCI Biotechnology: Pharmaceutical Preparations
- Sector
- ACM Consumer Discretionary
- ITCI Health Care
- Exchange
- ACM Nasdaq
- ITCI Nasdaq
- Market Cap
- ACM 12.8B
- ITCI 13.5B
- IPO Year
- ACM 2007
- ITCI N/A
- Fundamental
- Price
- ACM $92.50
- ITCI $131.81
- Analyst Decision
- ACM Strong Buy
- ITCI Buy
- Analyst Count
- ACM 8
- ITCI 13
- Target Price
- ACM $120.38
- ITCI $106.58
- AVG Volume (30 Days)
- ACM 1.0M
- ITCI 2.0M
- Earning Date
- ACM 05-05-2025
- ITCI 05-06-2025
- Dividend Yield
- ACM 1.12%
- ITCI N/A
- EPS Growth
- ACM 685.21
- ITCI N/A
- EPS
- ACM 3.50
- ITCI N/A
- Revenue
- ACM $16,219,730,000.00
- ITCI $680,852,000.00
- Revenue This Year
- ACM $6.71
- ITCI $40.64
- Revenue Next Year
- ACM $5.56
- ITCI $58.53
- P/E Ratio
- ACM $21.39
- ITCI N/A
- Revenue Growth
- ACM 8.89
- ITCI 46.62
- 52 Week Low
- ACM $82.23
- ITCI $64.09
- 52 Week High
- ACM $118.56
- ITCI $131.87
- Technical
- Relative Strength Index (RSI)
- ACM 36.39
- ITCI 85.59
- Support Level
- ACM $93.97
- ITCI $131.19
- Resistance Level
- ACM $96.74
- ITCI $131.79
- Average True Range (ATR)
- ACM 1.97
- ITCI 0.13
- MACD
- ACM 0.17
- ITCI -0.41
- Stochastic Oscillator
- ACM 7.26
- ITCI 91.18
About ACM AECOM
Aecom is one of the largest global providers of design, engineering, construction, and management services. It serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $14.4 billion in sales and $847 million in adjusted operating income in fiscal 2023.
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.